Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C2 | P52895 | 1/20 | 0.38 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.31 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.31 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.31 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.31 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.31 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.31 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.31 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.31 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1338710 | 0.89 | AKR1C2 (0.42) | AKR1C2AKR1C1CYP11B1CYP11B2PRKAB2 | |
| SCHEMBL8750439 | 0.81 | IDO1 (0.43) | AKR1C2AKR1C1 | |
| SCHEMBL18905322 | 0.79 | AKR1C2 (0.38) | AKR1C2AKR1C1CYP11B1CYP11B2PRKAB2 | |
| SCHEMBL14615251 | 0.79 | CHRNA7 (0.42) | AKR1C2AKR1C1 | |
| SCHEMBL7615009 | 0.79 | CHRNA7 (0.42) | AKR1C2AKR1C1 | |
| SCHEMBL10417418 | 0.77 | AKR1C2 (0.37) | AKR1C2AKR1C1CYP11B1CYP11B2PRKAB2 | |
| SCHEMBL17771762 | 0.77 | ADRB2 (0.52) | AKR1C2AKR1C1 | |
| SCHEMBL16177721 | 0.77 | CYP2A6 (0.40) | AKR1C2AKR1C1 | |
| SCHEMBL4921245 | 0.77 | TDP1 (0.44) | AKR1C2AKR1C1PRKAB2PRKAG1PRKAA2 | |
| SCHEMBL2213997 | 0.77 | AKR1C2 (0.37) | AKR1C2AKR1C1CYP11B1CYP11B2PRKAB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1963319-B1 | HETEROARYLPYRROLOPYRIDINONES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2012-04-11 | — | — | EP | disclosed |
| US-7618982-B2 | Heteroarylpyrrolopyridinones active as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2009-11-17 | — | — | US | disclosed |
| EP-1660085-B1 | PYRIDYLPYRROLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | PFIZER ITALIA SRL (IT) | 2008-10-15 | — | — | EP | disclosed |
| EP-1660475-B1 | PYRIMIDYLPYRROLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | PFIZER ITALIA SRL (IT) | 2008-05-28 | — | — | EP | disclosed |
| US-7279575-B2 | Pyrimidylpyrrole derivatives active as kinase inhibitors | PFIZER ITALIA S.R.L. (IT) | 2007-10-09 | — | — | US | disclosed |
| WO-2007068728-A2 | N-SUBSTITUTED PYRROLOPYRIDINONES ACTIVE AS KINASE INHIBITORS | PFIZER ITALIA SRL (IT) | 2007-06-21 | — | — | WO | disclosed |
| US-20070142414-A1 | N-substituted pyrrolopyridinones active as kinase inhibitors | PHARMACIA ITALIA S.P.A. (IT) | 2007-06-21 | — | — | US | disclosed |
| US-20070142415-A1 | Heteroarylpyrrolopyridinones active as kinase inhibitors | PHARMACIA ITALIA S.P.A. (IT) | 2007-06-21 | — | — | US | disclosed |
| EP-1660085-A1 | PYRIDYLPYRROLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | Pharmacia Italia S.p.A. (IT) | 2006-05-31 | — | — | EP | disclosed |
| US-20050043323-A1 | Pyrimidylpyrrole derivatives active as kinase inhibitors | PHARMACIA ITALIA S.P.A. (IT) | 2005-02-24 | — | — | US | disclosed |
| US-20050043346-A1 | Pyridylpyrrole derivatives active as kinase inhibitors | PHARMACIA ITALIA S.P.A. (IT) | 2005-02-24 | — | — | US | disclosed |
| WO-2005013986-A1 | PYRIDYLPYRROLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | PHARMACIA ITALIA S.P.A. (IT) | 2005-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043346-A1 | Pyridylpyrrole derivatives active as kinase inhibitors | MAP3K6, MAP3K5, MAP4K2 | AKR1C2 2031/4885AKR1C1 2048/4885CYP11B1 2575/4885 |
| US-20050043323-A1 | Pyrimidylpyrrole derivatives active as kinase inhibitors | TYMP, DTYMK, DCK | AKR1C2 1689/4885AKR1C1 1727/4885CYP11B1 2546/4885 |
| US-20070142415-A1 | Heteroarylpyrrolopyridinones active as kinase inhibitors | MAP3K1, MAP3K19, MAP3K3 | AKR1C2 1846/4885AKR1C1 1603/4885CYP11B1 2336/4885 |
| US-20070142414-A1 | N-substituted pyrrolopyridinones active as kinase inhibitors | CDK2, MAP3K19, MAP3K7 | AKR1C2 1778/4885AKR1C1 1373/4885CYP11B1 2408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.